Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects
- 1 June 2006
- journal article
- Published by Springer Nature in Leukemia
- Vol. 20 (8) , 1441-1445
- https://doi.org/10.1038/sj.leu.2404265
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBlood, 2005
- Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsBlood, 2004
- High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalitiesAnnals of Hematology, 2003
- Campath-1H–Induced Complete Remission of Chronic Lymphocytic Leukemia despitep53Gene Mutation and Resistance to ChemotherapyNew England Journal of Medicine, 2002
- Surfing the p53 networkNature, 2000
- p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor PrognosisBlood, 1998
- p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell, 1993